Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489727 | 0.96 | HTR2A (0.55) | HTR2AHTR2CHTR7CYP2D6DHODH | |
| SCHEMBL26326631 | 0.94 | DHODH (0.54) | HTR2AHTR2CHTR7CYP2D6DHODH | |
| SCHEMBL1348883 | 0.91 | HTR2A (0.58) | HTR2AHTR2CHTR7CYP2D6DHODH | |
| SCHEMBL15994961 | 0.82 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6DHODH | |
| SCHEMBL16861567 | 0.82 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6DHODH | |
| SCHEMBL30910924 | 0.82 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6DHODH | |
| SCHEMBL3303526 | 0.82 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6HTR6 | |
| SCHEMBL16861667 | 0.82 | HTR2A (0.51) | HTR2AHTR2CHTR7CYP2D6DHODH | |
| SCHEMBL21911551 | 0.81 | HTR2A (0.50) | HTR2AHTR2CHTR7CYP2D6DHODH | |
| SCHEMBL3394400 | 0.80 | HTR2A (0.64) | HTR2AHTR2CHTR7CYP2D6HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| EP-4452966-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| WO-2023115149-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| EP-3087071-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9458156-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| WO-2015100282-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| EP-2148869-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP9 | HTR2A 4447/4885HTR2C 4566/4885HTR7 4307/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | HTR2A 2445/4885HTR2C 1659/4885HTR7 2497/4885 |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | HTR2A 3747/4885HTR2C 3248/4885HTR7 3414/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | HTR2A 4312/4885HTR2C 4257/4885HTR7 4040/4885 |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | HTR2A 227/4885HTR2C 367/4885HTR7 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.